|
Three top stomach cancer experts came away from the American Society of Clinical Oncology (ASCO) Annual Conference in Chicago earlier this month feeling optimistic about several promising treatments, they said during a webinar on June 11.
The webinar was hosted by seven organizations dedicated to advancing cures for gastric cancer, including the Gastric Cancer Foundation. The discussion was moderated by former Gastric Cancer Foundation grantee Samuel Klempner, MD, of Massachusetts General Hospital and Harvard Medical School. The panel included Frank Blandon, a stomach cancer patient who weighed in on his experiences being treated for the past two years.
The panelists covered a range of advances discussed at ASCO, including new surgical regimens, combination treatments and novel drugs. Panelist Yelena Janjigian, MD, of Memorial Sloan Kettering Cancer Center was particularly impressed by results from a trial of Ziihera (zanidatamab) combinations in the first-line treatment of patients with HER2-positive gastric cancer. Data shared at ASCO showed that combining Ziihera with Tevimbra (tislelizumab), a PD-1 immune checkpoint inhibitor and chemotherapy significantly improved progression-free survival regardless of whether patients’ tumors tested positive or negative for PD-L1—a tumor biomarker commonly used to determine patients’ likelihood to respond to immunotherapy.
Webinar panelist Elena Elimova, MD, of the University of Toronto—who is one of the investigators in the Ziihera trial—suggested that the positive results “open this treatment option for actually all comers. So that is what’s new and that’s what’s exciting.” She added that some gastric cancer patients she has treated as part of the trial have been survivors for more than five years.
The panelists also expressed optimism about emerging experimental treatments that target other genetic abnormalities in tumors. They include savolitinib, which inhibits a tumor-driving receptor called MET. An estimated 5% of gastric cancer patients have MET-positive tumors. In a phase 2 trial in China that was presented at ASCO, savolitinib shrank tumors in one-third of patients—results that could pave the way for future studies.
Klempner said he’s optimistic that the combination of effective targeted drugs and improved access to next-generation genetic sequencing that can identify rare tumor biomarkers like MET will ultimately improve the prognosis for gastric cancer patients. “This was the…largest trial with an active [MET-targeted drug] that worked,” Klempner said. “Better drugs, better patient selection—it’s a pretty good recipe to get to success.”
If you missed the live event, the full recording is available now.
Watch the webinar >>
This was the first in a planned series of educational webinars co-hosted by a collaborative including Debbie's Dream Foundation, Gastric Cancer Foundation, GI Cancers Alliance, Hope for Stomach Cancer, My Gut Feeling, No Stomach for Cancer, and Stomach Cancer UK. Stay tuned for our next webinar following the 2026 ESMO Gastrointestinal Cancers Congress in July.
|